Introduction/Overview
Natural products, as an important source of drug discovery, have long contributed numerous lead compounds with novel structures and unique mechanisms of action to human health. In the field of anti-tumor drug development, searching for efficient and low toxicity active ingredients from traditional medicinal plants has always been a research hotspot. Tenghuang（Garcinia hanburyi Hook.f.）， As a traditional Chinese medicine and natural resin, its extract is used in folk medicine to treat diseases such as inflammation, infection, and tumors. Tenghuang is rich in a series of unique bridged ring structures of ketone compounds, among which Gambogenic acid (GNA) has attracted much attention for its significant anti-tumor activity and novel molecular mechanism of action.
Gambogenic acid (CAS number: 173932-75-7) is a polycyclic polyisoprenylated xanthone (PPAP) compound isolated from Tenghuang. Early research mainly focused on its broad-spectrum cytotoxicity, but in recent years, with the deepening understanding of the role of epigenetic regulation in tumor occurrence and development, the targets of GNA have gradually been elucidated. Of particular importance, research has found that Gambogenic acid can specifically inhibit the activity of histone methyltransferase EZH2 (Enhancer of Zeste Homolog 2) by covalently binding to the key cysteine residue (Cys668) in its SET domain, inducing ubiquitination degradation of EZH2 protein and reversing the malignant phenotype of tumor cells. This discovery not only reveals the deep molecular basis of GNA's anti-tumor activity, but also provides a new chemical scaffold for the development of small molecule inhibitors targeting EZH2.
This article aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, pharmacological evaluation, and clinical application prospects of Gambogenic acid, in order to provide comprehensive literature support for the in-depth research and development of this natural product.
Chemical structure and physicochemical properties
Gambogenic acid belongs to the polycyclic polyisoprenylated ketone family, and its chemical structure is highly complex and unique. The core skeleton of this compound is a highly oxidized ketone core, which is connected to multiple isopentenyl side chains and forms a unique cage like bridged ring system. This complex spatial configuration endows GNA with special biological activity that distinguishes it from other ketone compounds.
From the perspective of physical and chemical properties, the molecular formula of Gambogenic acid is C ∝₈ H ₄₆ O ₈, with a molecular weight of 630.7780 g/mol, belonging to a medium to large natural product molecule. Its lipid water partition coefficient (LogP) is 6.7402, indicating that it has high lipid solubility, which is consistent with the structural characteristics of its polyisoprene side chains. High lipid solubility is beneficial for compounds to penetrate cell membranes, but it may also lead to poor water solubility. The water solubility parameter of GNA is 0.0420 mg/mL, which belongs to insoluble compounds, which to some extent limits its bioavailability and the design of administration routes. The topological polar surface area (TPSA) is 130.3600 Å ², which is a relatively high value and usually indicates that the oral absorption of the compound may be limited and it is not easy to penetrate the blood-brain barrier (BBB). In fact, its blood-brain barrier penetration assessment is "low", indicating that GNA may not have an advantage in the treatment of central nervous system related diseases, but it may also reduce the toxic side effects of the central nervous system.
In addition, in terms of early safety screening, the hERG inhibition risk assessment of Gambogenic acid was' no ', indicating a low risk of causing QT interval prolongation and arrhythmia in the heart. The Ames test result was 0.0, indicating that it did not show significant mutagenicity in the bacterial recovery mutation test, which provides preliminary safety assurance for its subsequent development. However, these parameters are only computer simulation predictions or preliminary in vitro experimental results, and comprehensive toxicological evaluation still needs to be conducted at multiple levels in vitro and in vivo.
Plant sources and extraction methods
The main plant source of Gambogenic acid is the genus Tenghuang, especially Tenghuang（Garcinia hanburyi Dry resin of Hook. f. The vine yellow tree is mainly distributed in Southeast Asia, such as Thailand, Cambodia, Vietnam, as well as Yunnan, Guangxi and other places in China. When a tree trunk is cut, it secretes a yellow or orange yellow resin, which is collected and dried to obtain the traditional Chinese medicine Tenghuang. As a traditional Chinese medicine, Tenghuang has the effects of breaking blood and dispersing nodules, attacking toxins and ulcers, and is commonly used to treat carbuncles, swelling and injuries caused by falls and injuries. Modern pharmacological research has shown that the main active ingredients in Tenghuang are a series of PPAPs, among which Gambogenic acid is structurally similar to another famous natural product, Gambogic acid, but has different activities.
Extracting and purifying Gambogenic acid from rattan resin typically requires the use of modern chromatographic separation techniques. Traditional extraction methods include solvent extraction, with commonly used solvents such as ethanol, methanol, or ethyl acetate. Due to the complex composition of rattan resin, which contains a large amount of resin acids, pigments, and other ketone compounds, the crude extract needs further separation and purification. The classic separation process usually includes: first, reflux extraction or ultrasound assisted extraction of rattan powder with organic solvents to obtain the total extract; Then, preliminary separation was carried out by silica gel column chromatography and ODS (octadecylsilane bonded silica gel) reverse phase column chromatography, and gradient elution was performed using petroleum ether ethyl acetate or methanol water systems with different ratios; Finally, by combining preparative high-performance liquid chromatography (Prep HPLC) technology, high-purity Gambogenic acid monomers can be obtained. During the separation process, the identification of GNA typically relies on nuclear magnetic resonance spectroscopy (NMR), high-resolution mass spectrometry (HR-MS), and chromatographic behavior compared to standard samples.
It is worth noting that due to the extremely similar structure between GNA and Gambogic acid, precise control of conditions is required during the separation process to achieve effective separation of the two. In recent years, with the promotion of green chemistry concepts, some new extraction technologies, such as supercritical fluid extraction (SFE) and high-speed countercurrent chromatography (HSCCC), have also been attempted for the extraction and separation of active ingredients in Tenghuang, aiming to improve extraction efficiency, reduce costs, and minimize the use of organic solvents.
Pharmacological activity research
The pharmacological activity research of Gambogenic acid mainly focuses on the field of anti-tumor, while also involving other biological activities such as anti-inflammatory and antibacterial.
1. Antitumor activity
GNA exhibits significant proliferation inhibition and induces apoptosis in various types of tumor cell lines. Research shows that it is cytotoxic to melanoma, lung cancer, breast cancer, liver cancer, stomach cancer, colorectal cancer, prostate cancer, leukemia and other cell lines, and the IC ₀ value is usually in the micromolar level. For example, in melanoma cells, GNA can effectively inhibit cell viability, induce cell cycle arrest in G0/G1 or G2/M phases, and promote cell apoptosis by activating the mitochondrial apoptosis pathway (upregulating Bax, downregulating Bcl-2) and death receptor pathway (activating Caspase-8). In addition, GNA can also inhibit the migration and invasion ability of tumor cells, which is related to its regulation of matrix metalloproteinases (such as MMP2) expression.
2. Anti inflammatory and immune regulatory activity
In addition to its direct anti-tumor effect, GNA also exhibits certain anti-inflammatory activity. It can inhibit the production of nitric oxide (NO) and prostaglandin E ₂ (PGE ₂) in macrophages induced by lipopolysaccharide (LPS), and downregulate the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). These effects may be related to the inhibition of the activation of the nuclear factor kappa B (NF - κ B) signaling pathway. In terms of tumor immune microenvironment, GNA has been found to regulate the activity of indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 is a key enzyme for tumor immune escape, and the inhibition of it by GNA may help restore the anti-tumor immune function of T cells, suggesting the potential of GNA as an immune checkpoint regulator.
3. Other activities
Preliminary studies have also found that GNA has a certain inhibitory effect on certain bacteria and fungi, but its antibacterial activity is much weaker than its anti-tumor activity. In addition, it has been reported that GNA can induce the expression of antioxidant enzymes in normal cells by activating the nuclear factor E2 related factor 2 (NFE2L2, also known as Nrf2) pathway, which may explain its low toxicity characteristics in certain models.
Mechanism of action and molecular targets
The core of the anti-tumor mechanism of Gambogenic acid lies in its specific inhibition of the epigenetic regulatory factor EZH2. EZH2 is the catalytic subunit of polycomb inhibitory complex 2 (PRC2), responsible for catalyzing the trimethylation of histone H3 lysine 27 (H3K27me3), thereby silencing the transcription of target genes. EZH2 is highly expressed or functionally mutated in various malignant tumors, and is closely related to tumor proliferation, metastasis, drug resistance, and poor prognosis.
1. Covalent binding and degradation targeting EZH2
Research has found that Gambogenic acid is not a traditional competitive inhibitor, but rather acts as a covalent inhibitor. It can specifically form covalent bonds with the cysteine 668 site (Cys668) in the SET domain of EZH2 protein, which is responsible for methyltransferase activity. This irreversible binding pattern endows GNA with strong inhibitory power. More importantly, the binding of GNA to EZH2 not only inhibits its enzymatic activity, but also triggers ubiquitination modification of EZH2 protein, which is subsequently degraded through the ubiquitin proteasome pathway. This dual mechanism of "inhibition and degradation" enables GNA to more thoroughly eliminate the function of EZH2 in tumor cells.
2. Impact on downstream signaling pathways
By inhibiting and degrading EZH2, GNA leads to a significant decrease in intracellular H3K27me3 levels, thereby reactivating tumor suppressor genes silenced by EZH2. These genes include cell cycle regulatory factors (such as p21, p27), apoptosis promoting factors (such as BIM), and tumor metastasis suppressor factors. In addition, the regulation of EZH2 by GNA also interacts with other key signaling pathways. For example, in melanoma, GNA can inhibit the phosphorylation activation of the STAT3 signaling pathway and downregulate the expression of downstream target genes such as Bcl-2 and IDO1. Meanwhile, GNA can also activate the AMPK signaling pathway, which is closely related to energy metabolism regulation and cell growth inhibition. In addition, the activation of NFE2L2 (Nrf2) by GNA may be a compensatory response of cells to oxidative stress, but its specific role in the overall anti-tumor effect of GNA needs further investigation.
3. Multi target characteristics
Although EZH2 is currently confirmed as a key target of GNA, given the multi-target nature of natural products, GNA may also exert anti-tumor effects through other pathways. For example, it may directly or indirectly affect the activity of melanoma related targets such as TYR (tyrosinase), PRKCA (protein kinase C alpha), MAPT (microtubule associated protein Tau), and MMP2. These multi-target effects may collectively form the molecular basis for the anti-tumor activity of GNA and help overcome the problem of resistance to single target drugs.
Evaluation of drug properties and pharmacokinetics
Transforming Gambogenic acid from a natural product into a clinical drug faces a series of challenges in drug formulation, mainly focused on solubility, stability, and pharmacokinetic properties.
1. Solubility and formulation strategy
As mentioned earlier, the water solubility of GNA is extremely poor (0.0420 mg/mL), which severely limits its oral bioavailability. A high LogP value (6.7402) also suggests that it is prone to aggregation and precipitation in aqueous environments. Therefore, developing appropriate formulation techniques is the key to developing GNA drugs. Current research has attempted various strategies, including the preparation of liposomes, nanoparticles, polymer micelles, cyclodextrin inclusion complexes, and phospholipid complexes. These nano drug delivery systems not only enhance the apparent solubility of GNA, but also enrich drugs in tumor tissues through passive targeting (EPR effect) or active targeting modification, thereby improving efficacy and reducing systemic toxicity.
2. Pharmacokinetic characteristics
There are relatively limited research reports on the pharmacokinetics of GNA in vivo. Preliminary animal experiments have shown that after intravenous injection, GNA is widely distributed in the body, but its elimination half-life may be short. Its oral bioavailability is extremely low, mainly due to its low solubility and possible first pass effects. The metabolic pathway of GNA in the body is not yet clear, and it is speculated that it may involve oxidative metabolism of cytochrome P450 enzyme system and binding reactions of glucuronic acid or sulfuric acid. Due to its high lipid solubility, GNA may easily accumulate in adipose tissue and undergo hepatic intestinal circulation. In addition, the low penetration of GNA into the blood-brain barrier may limit its application in brain tumors, but it may also avoid toxicity to the central nervous system.
3. Safety evaluation
Preliminary toxicological data shows that GNA is negative in the in vitro Ames test and has a low risk of hERG inhibition, indicating a low risk of genetic and cardiac toxicity. However, in animal experiments, high doses of GNA may still exhibit certain toxicity, such as weight loss and liver and kidney function damage. The therapeutic window (i.e. the range between effective dose and toxic dose) may be relatively narrow. Therefore, in subsequent development, it is necessary to expand its therapeutic window through structural modification or optimization of the drug delivery regimen.
Clinical application prospects and prospects
Gambogenic acid, as a natural product with unique structure and novel mechanism of action, has shown great potential in the field of anti-tumor drug development, especially for EZH2 driven malignant tumors.
1. Treatment of melanoma
Melanoma is a highly malignant skin cancer, and its incidence rate is increasing year by year. EZH2 plays an important role in the occurrence, development, and metastasis of melanoma. GNA targets the degradation of EZH2, inhibits the proliferation, migration, and invasion of melanoma cells, and induces their apoptosis. Meanwhile, GNA can also inhibit the expression of IDO1, which may help reverse the tumor immune suppressive microenvironment. Therefore, GNA is expected to become a novel candidate drug for the treatment of melanoma, especially for patients who are resistant or intolerant to existing targeted therapies such as BRAF inhibitors or immunotherapy such as PD-1 inhibitors.
2. Combination therapy strategy
Given the multi-target nature of GNA, combination therapy may be an effective strategy to improve its efficacy and overcome drug resistance. For example, the combination of GNA with chemotherapy drugs such as cisplatin and paclitaxel may produce a synergistic effect. More importantly, the combined application of GNA and immune checkpoint inhibitors (such as anti-PD-1/PD-L1 antibodies) deserves further exploration. GNA may enhance the immunogenicity of tumor cells and relieve T cell immune suppression by inhibiting EZH2 and IDO1, thereby forming a synergistic effect with immune checkpoint inhibitors to transform from "cold tumors" to "hot tumors".
3. Structural optimization and derivative development
The complex chemical structure of GNA provides extensive modification space for medicinal chemists. By modifying the structure of its ketone core or isopentenyl side chain, the aim is to improve its water solubility, metabolic stability, targeting selectivity, and reduce toxicity. For example, introducing hydrophilic groups such as phosphate groups and amino sugars to improve solubility; Alternatively, through prodrug design, the carboxyl or phenolic hydroxyl groups of GNA can be modified to release the original drug in a specific environment within the body. Developing GNA derivatives with higher activity and better drug resistance is an important direction to promote the clinical application of this compound.
4. Challenges Faced
Despite the bright prospects, the clinical translation of GNA still faces many challenges. Firstly, its complex chemical structure leads to high costs for full or semi synthesis, and currently relies mainly on natural extraction, which is difficult to meet the needs of large-scale production. Secondly, poor water solubility and unknown in vivo metabolic behavior are the main bottlenecks for its drug development. Finally, although EZH2 is its main target, its inhibition of EZH2 function in normal tissues may bring potential long-term toxicity, such as affecting the self-renewal of hematopoietic stem cells. Therefore, more in-depth and long-term toxicological studies are needed to evaluate its safety.
Conclusion
Gambogenic acid, as a representative polycyclic polyisoprenylated ketone in Tenghuang, occupies an important position in the field of natural product pharmacology due to its unique chemical structure and original mechanism of inducing EZH2 degradation through covalent binding. The research process of GNA vividly illustrates the shift of modern drug discovery from "activity oriented isolation" to "mechanism oriented research", from broad-spectrum cytotoxicity to precise epigenetic target regulation. Its anti-tumor activity demonstrated in various malignant tumors such as melanoma, as well as preliminary safety evaluation, have laid a solid foundation for its use as an anti-tumor lead compound.
However, from laboratory discovery to clinical application, GNA still has a long way to go. The future research focus should be on: 1) developing efficient and green chemical or biological synthesis methods to solve the problem of drug sources; 2) Utilizing advanced formulation technology to overcome its low solubility and bioavailability; 3) Through systematic pharmacokinetic and toxicological studies, comprehensively evaluate its in vivo behavior and safety; 4) Based on its mechanism of action, explore a reasonable combination therapy plan, especially in combination with immunotherapy. With the continuous deepening of understanding of the biological functions of EZH2 and the advancement of medicinal chemistry and formulation technology, Gambogenic acid and its derivatives are expected to become a new type of targeted epigenetic regulation anti-tumor drug in the future, bringing new therapeutic hope to cancer patients.
